Today the US Food and Drug Administration will receive its first submission of a candidate vaccine to fight the pandemic coronavirus.
Pharmaceutical giant Pfizer and German biotech firm BioNTech announced early this morning that they are submitting the formal request to obtain an Emergency Use Authorization (EUA) from the FDA for the companies’ mRNA vaccine, BNT162b2.
The submission follows the celebrated news just Wednesday that the companies had wrapped up their Phase III trial and found the vaccine to be 95-percent effective at preventing symptomatic COVID-19, the disease caused by the coronavirus, SARS-CoV-2.
Though full data on the trial has not been published, the companies announced by press release that the vaccine appeared consistently effective across racial and ethnic backgrounds and was 94-percent effective in people over age 65—an age group at highest risk of severe disease. Trial data also indicated that the vaccine was protective against severe disease ...
Copyright of this story solely belongs to arstechnica.com . To see the full text click HERE